Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Isomorphic Labs is a London-based drug developer that’s owned and operated by Alphabet Inc. The company was founded in 2021 as an offshoot from DeepMind , Google’s multidisciplinary AI ...

The company was spun out of Google DeepMind in 2021, and is built on the breakthrough AlphaFold system, an AI model that stunned the scientific community by accurately predicting ...

Isomorphic Labs, a drug discovery company spun out of Google DeepMind, is about to make a historic breakthrough ... DeepMind’s revolutionary AlphaFold AI system gave birth to Isomorphic Labs, which ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to know ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Isomorphic Labs is setting up an office in Cambridge, Mass., as it prepares for clinical trials of some of its AI-enabled drug candidates. Skip to Main Content Manage alerts for this article ...

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? May 27, 2025 — 10:00 am EDT. ... Rivalry from companies like Relay Therapeutics, Isomorphic Labs, ...